Sino-India Pharmaceutical Exchange- Live Stream Webinar
China has already entered post-COVID era from late 2020 with full resumption of work and production. While China is working to give full play to its huge domestic market, it is still committed to intercountry cooperation. More and more overseas pharma companies are exploring business and partnership opportunities in China, eager for a share of the big cake.
In the past 3 to 4 years, industry structure in pharmaceuticals has changed with remarkable shifts in the leader board. Four of the top ten players, including the market leader, are new entrants. India and China are mutual reliable partner especially in pharma industry. For Indian API and finished dosage companies, internationalization is a common pursuit, and the growing Chinese pharmaceutical market is an opportunity deserving to be firmly grasped. Therefore, it is important to understand China's constantly updated drug registration and review, approval policies and procedures, and to find local reliable and committed partners to efficiently expand business.
CPhI & P-MEC China launches the “E-Trade Season” from March - June 2021 to provide the pharmaceutical industry with online learning and trading opportunities. This includes months of informative content and a targeted matchmaking service - delivering over 8 themed webinar series and showcasing high-quality pharma suppliers from 4 popular themes. The Sino-India Pharmaceutical Exchange Session will focus on Indian and Chinese pharma market, building a learning and networking platform and contributing to the advancement of the connection between India & China.
Development Trend of China’s API Industry and Cooperation Prospect with India
Requirements and Practical Procedures of Imported Drug Registration in China
Development of Indian APIs and Generic Drugs in Indian and Chinese Market
Panel Discussion: Investment, Deal Making and Partnership Establishment in China